Trimodulin: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 166 patientsc19early.org

Trimodulin for COVID-19

Serious outcome risk
Trimodulin
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−17%
Mortality (1)−17%
Ventilation (1)−9%
RCTs (1)−17%
Late (1)−17%
00.511.5+
← Trimodulin
reduces riskIncreased
risk →
c19early.org
October 2026

Trimodulin COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.16death18/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.1618/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Agafina (DB RCT)−9%1.09 · 0.79–1.4984 (n)82 (n)ESsCOVID
Late treatment−9%1.09 · 0.79–1.4984 (n)82 (n)9% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−9%1.09 · 0.79–1.4984 (n)82 (n)9% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.16death18/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.16death18/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.1618/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →
c19early.org
October 2026

Trimodulin COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Agafina (DB RCT)−17%1.17 · 0.63–2.16death18/8415/82ESsCOVID
Late treatment−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.63
All studies−17%1.17 · 0.63–2.1618/8415/8217% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6300.511.52+
Rotate screen for more detailsIncrease width for more details
← Trimodulin
reduces riskTrimodulin
increases risk →